SFM
PRLD icon

Sphera Funds Management’s Prelude Therapeutics PRLD Stock Holding History

Sphera Funds Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Buy
558,339
+435,587
+355% +$1.14M 0.3% 79
2025
Q4 		$356K Buy
+122,752
New +$207K 0.07% 94

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sphera Funds Management's PRLD Position: Q1 2026 in Review

Sphera Funds Management increased its Prelude Therapeutics (PRLD) stake by 355% in Q1 2026, buying an estimated $1.14M and bringing the position to 558,339 shares worth $1.91M. The position accounts for 0.3% of the portfolio, ranked #79.

Sphera Funds Management first reported a position in PRLD in Q4 2025 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Sphera Funds Management held 558,339 shares of Prelude Therapeutics worth $1.91M as of Q1 2026.
  • Sphera Funds Management bought 435,587 Prelude Therapeutics shares in Q1 2026, an estimated $1.14M.
  • Prelude Therapeutics made up 0.3% of Sphera Funds Management's portfolio in Q1 2026, its #79 holding.
  • Sphera Funds Management first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.